L. Demir, Duygu Bayır, Ruhengiz Özdoğan, B. Yıldız, M. Dinçer
{"title":"Pazopanib和舒尼替尼在转移性肾细胞癌中的实际比较:一项单中心研究，重点是低风险患者","authors":"L. Demir, Duygu Bayır, Ruhengiz Özdoğan, B. Yıldız, M. Dinçer","doi":"10.37047/jos.2020-76764","DOIUrl":null,"url":null,"abstract":"The Memorial Sloan Kettering Cancer Center (MSKCC) and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) have classified RCC according to clinical characteristics into three risk groups: favorable, intermediate, and poor. Previous reports have demonstrated that patients with poor-risk features (according to MSKCC criteria and neutrophil and platelet counts) presented a significantly shorter overall survival (OS) than patients with favorableto intermediate-risk features, and the twoyear survival rate of poor-risk patients did not exceed 7%, while that of the favorableto intermediate-risk patients was 53-75%.4,5","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"6 1","pages":"153-163"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Real-World Comparison of Pazopanib Versus Sunitinib in Metastatic Renal Cell Carcinoma: Focus on Poor-Risk patients, A Single-Center Study\",\"authors\":\"L. Demir, Duygu Bayır, Ruhengiz Özdoğan, B. Yıldız, M. Dinçer\",\"doi\":\"10.37047/jos.2020-76764\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The Memorial Sloan Kettering Cancer Center (MSKCC) and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) have classified RCC according to clinical characteristics into three risk groups: favorable, intermediate, and poor. Previous reports have demonstrated that patients with poor-risk features (according to MSKCC criteria and neutrophil and platelet counts) presented a significantly shorter overall survival (OS) than patients with favorableto intermediate-risk features, and the twoyear survival rate of poor-risk patients did not exceed 7%, while that of the favorableto intermediate-risk patients was 53-75%.4,5\",\"PeriodicalId\":31838,\"journal\":{\"name\":\"Journal of Oncological Sciences\",\"volume\":\"6 1\",\"pages\":\"153-163\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Oncological Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.37047/jos.2020-76764\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oncological Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37047/jos.2020-76764","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
A Real-World Comparison of Pazopanib Versus Sunitinib in Metastatic Renal Cell Carcinoma: Focus on Poor-Risk patients, A Single-Center Study
The Memorial Sloan Kettering Cancer Center (MSKCC) and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) have classified RCC according to clinical characteristics into three risk groups: favorable, intermediate, and poor. Previous reports have demonstrated that patients with poor-risk features (according to MSKCC criteria and neutrophil and platelet counts) presented a significantly shorter overall survival (OS) than patients with favorableto intermediate-risk features, and the twoyear survival rate of poor-risk patients did not exceed 7%, while that of the favorableto intermediate-risk patients was 53-75%.4,5
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
